Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 33.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 66.7%Moderate 0 · 0%High 0 · 0%

Subcutaneous unfractionated heparin vs low molecular weight heparin

Asymptomatic VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

The review found no eligible studies for this question.

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Subcutaneous unfractionated heparin vs low molecular weight heparin

Symptomatic recurrent VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent VTE at 3 months compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
OR 1.01 [0.63, 1.63]
5 studies · 2156 participants
Low

Subcutaneous unfractionated heparin vs low molecular weight heparin

Symptomatic recurrent DVT at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent DVT at 3 months compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
OR 1.38 [0.73, 2.63]
3 studies · 1566 participants
Low